Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdOx2 RabG + inactivated rabies vaccine
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
ChAdOx2 RabG + inactivated rabies vaccine is a combination immunization regimen being developed by the University of Oxford for the prevention of rabies. The regimen consists of ChAdOx2 RabG, a viral vector vaccine utilizing a non-replicating simian adenovirus (ChAdOx2) to express the full-length glycoprotein of the Evelyn-Rokitnicki-Abelseth (ERA) strain of the rabies virus, coadministered with a licensed inactivated rabies vaccine (IRV) such as Verorab. This approach leverages the high immunogenicity of the ChAdOx2 platform—the same technology used in the Oxford-AstraZeneca COVID-19 vaccine—combined with traditional inactivated vaccine technology to potentially provide more rapid or durable protection. It is currently being evaluated in Phase II clinical trials in Tanzania to assess safety and immunogenicity in healthy adults.
- Brand names
- Verorab
- Other names
- ChAdOx2 RabG + IRVChAdOx2-RabG + inactivated rabies vaccine
02
Targets
RABV-G (Rabies virus glycoprotein)
Beyond the preview
Go deeper on ChAdOx2 RabG + inactivated rabies vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdOx2 RabG + inactivated rabies vaccine.